Omeros is a clinical-stage biopharma company committed to discovering, developing and commercializing first-in-class immunology, immuno-oncology and anti-addiction therapeutics. Omeros’ pipeline is led by its complement franchise of late-stage drug candidates targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and MASP-3, the key activator of the alternative pathway, both implicated in hematological and other disorders.